Stock A246960 SCL SCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials SCL Science Inc.

Equities

A246960

KR7246960009

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
8,800 KRW +2.80% Intraday chart for SCL Science Inc. +9.05% -0.79%
02-07 H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc. CI
2023 H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 69,610 83,481 61,035 47,935 64,191
Enterprise Value (EV) 1 59,840 81,869 68,144 55,358 63,136
P/E ratio -17.2 x -27.4 x -12.1 x -7.57 x -11.1 x
Yield - - - - -
Capitalization / Revenue 100 x 140 x 120 x 130 x 48.6 x
EV / Revenue 86.4 x 137 x 134 x 150 x 47.8 x
EV / EBITDA -17.2 x -25.9 x -17.6 x -14.4 x -19.6 x
EV / FCF -27.6 x -21.7 x -8 x -16.5 x -13.5 x
FCF Yield -3.62% -4.62% -12.5% -6.07% -7.41%
Price to Book 4.62 x 6.45 x 6.06 x 3.74 x 3.42 x
Nbr of stocks (in thousands) 5,044 5,044 5,044 5,600 7,237
Reference price 2 13,800 16,550 12,100 8,560 8,870
Announcement Date 20-03-19 21-03-22 22-03-23 23-03-23 24-03-21
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 512.2 692.8 596.2 507.3 369.8 1,322
EBITDA 1 -2,267 -3,478 -3,155 -3,865 -3,849 -3,217
EBIT 1 -2,586 -3,901 -3,697 -4,538 -4,605 -4,017
Operating Margin -504.93% -563.06% -620.15% -894.52% -1,245.36% -303.85%
Earnings before Tax (EBT) 1 -2,574 -3,988 -3,289 -5,013 -5,984 -5,023
Net income 1 -2,574 -3,989 -3,047 -5,029 -5,972 -5,026
Net margin -502.6% -575.8% -511.16% -991.39% -1,614.99% -380.17%
EPS 2 -625.0 -800.3 -604.2 -997.0 -1,130 -800.0
Free Cash Flow 1 -1,393 -2,165 -3,780 -8,520 -3,362 -4,681
FCF margin -272.01% -312.56% -634.1% -1,679.55% -909.33% -354.05%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-19 20-03-19 21-03-22 22-03-23 23-03-23 24-03-21
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 7,109 7,424 -
Net Cash position 1 6,578 9,769 1,612 - - 1,055
Leverage (Debt/EBITDA) - - - -1.839 x -1.929 x -
Free Cash Flow 1 -1,393 -2,165 -3,780 -8,520 -3,362 -4,681
ROE (net income / shareholders' equity) -40.8% -32.4% -21.6% -43.4% -51.1% -31.3%
ROA (Net income/ Total Assets) -21% -17.2% -13.4% -11.5% -9.18% -8.24%
Assets 1 12,248 23,242 22,804 43,653 65,045 61,031
Book Value Per Share 2 2,138 2,990 2,566 1,998 2,288 2,597
Cash Flow per Share 2 79.90 1,160 114.0 204.0 319.0 693.0
Capex 1 27.8 285 1,819 6,343 340 2,374
Capex / Sales 5.43% 41.2% 305.03% 1,250.34% 91.95% 179.59%
Announcement Date 19-03-19 20-03-19 21-03-22 22-03-23 23-03-23 24-03-21
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SCL SCIENCE INC. Stock SCL Science Inc.
-0.79% 46.27M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A246960 Stock
  4. Financials SCL Science Inc.